| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.
|
J Clin Oncol
|
2005
|
3.50
|
|
2
|
An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort.
|
J Clin Oncol
|
2004
|
2.45
|
|
3
|
The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly.
|
J Clin Oncol
|
2003
|
2.32
|
|
4
|
KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803.
|
Clin Cancer Res
|
2009
|
2.02
|
|
5
|
Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3).
|
Cancer
|
2007
|
1.94
|
|
6
|
Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group.
|
Leuk Lymphoma
|
2008
|
1.61
|
|
7
|
Efficacy of radiotherapy for ovarian ablation: results of a breast intergroup study.
|
Cancer
|
2004
|
1.50
|
|
8
|
Recommendations for collection and handling of specimens from group breast cancer clinical trials.
|
J Clin Oncol
|
2008
|
1.50
|
|
9
|
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531).
|
Ann Oncol
|
2008
|
1.43
|
|
10
|
Impact of surgical and pathologic variables in rectal cancer: a United States community and cooperative group report.
|
J Clin Oncol
|
2001
|
1.42
|
|
11
|
Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial.
|
Cancer
|
2006
|
1.42
|
|
12
|
Prognostic value of proliferation, apoptosis, defective DNA mismatch repair, and p53 overexpression in patients with resected Dukes' B2 or C colon cancer: a North Central Cancer Treatment Group Study.
|
J Clin Oncol
|
2004
|
1.41
|
|
13
|
Cooperative research group members question advertisement.
|
Oncol Nurs Forum
|
2001
|
1.39
|
|
14
|
Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.28
|
|
15
|
Should elderly non-small-cell lung cancer patients be offered elderly-specific trials? Results of a pooled analysis from the North Central Cancer Treatment Group.
|
J Clin Oncol
|
2005
|
1.27
|
|
16
|
Phase III double-blind study of glutamine versus placebo for the prevention of acute diarrhea in patients receiving pelvic radiation therapy.
|
J Clin Oncol
|
2003
|
1.13
|
|
17
|
Evaluation of shark cartilage in patients with advanced cancer: a North Central Cancer Treatment Group trial.
|
Cancer
|
2005
|
1.11
|
|
18
|
Whole-brain radiotherapy and high-dose methylprednisolone for elderly patients with primary central nervous system lymphoma: Results of North Central Cancer Treatment Group (NCCTG) 96-73-51.
|
Int J Radiat Oncol Biol Phys
|
2006
|
1.08
|
|
19
|
Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2005
|
1.07
|
|
20
|
Importance of baseline mini-mental state examination as a prognostic factor for patients with low-grade glioma.
|
Int J Radiat Oncol Biol Phys
|
2004
|
1.03
|
|
21
|
Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB).
|
Support Care Cancer
|
2010
|
1.03
|
|
22
|
Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group.
|
Ann Oncol
|
2006
|
1.03
|
|
23
|
Prophylactic cranial irradiation in small-cell lung cancer: findings from a North Central Cancer Treatment Group Pooled Analysis.
|
Ann Oncol
|
2012
|
1.03
|
|
24
|
Oxaliplatin and capecitabine in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction and gastric cardia: a phase II study from the North Central Cancer Treatment Group.
|
Ann Oncol
|
2005
|
1.00
|
|
25
|
Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results.
|
J Neurooncol
|
2008
|
1.00
|
|
26
|
Model-based prediction of defective DNA mismatch repair using clinicopathological variables in sporadic colon cancer patients.
|
Cancer
|
2010
|
0.98
|
|
27
|
Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study.
|
Int J Radiat Oncol Biol Phys
|
2005
|
0.97
|
|
28
|
Adult patients with supratentorial pilocytic astrocytomas: a prospective multicenter clinical trial.
|
Int J Radiat Oncol Biol Phys
|
2004
|
0.96
|
|
29
|
Patient assessment of bowel function during and after pelvic radiotherapy: results of a prospective phase III North Central Cancer Treatment Group clinical trial.
|
J Clin Oncol
|
2007
|
0.86
|
|
30
|
A randomized phase II and pharmacokinetic study of dacarbazine in patients with recurrent glioma.
|
J Neurooncol
|
2000
|
0.85
|
|
31
|
Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633.
|
J Thorac Oncol
|
2010
|
0.84
|
|
32
|
A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
|
Cancer
|
2008
|
0.83
|
|
33
|
A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group.
|
Urology
|
2007
|
0.83
|
|
34
|
CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study.
|
Int J Gastrointest Cancer
|
2002
|
0.82
|
|
35
|
Phase 2 trial of paclitaxel polyglumex with capecitabine for metastatic breast cancer.
|
Am J Clin Oncol
|
2014
|
0.81
|
|
36
|
A phase II trial of edatrexate, vinblastine, adriamycin, cisplastin, and filgrastim (EVAC/G-CSF) in patients with non-small-cell carcinoma of the lungs: a North Central Cancer Treatment Group Trial.
|
Am J Clin Oncol
|
2001
|
0.80
|
|
37
|
Is bortezomib, a proteasome inhibitor, effective in treating cancer-associated weight loss? Preliminary results from the North Central Cancer Treatment Group.
|
Support Care Cancer
|
2005
|
0.78
|
|
38
|
Comparison of conventional dose and double dose carboplatin in patients receiving cyclophosphamide plus carboplatin for advanced ovarian carcinoma: a North Central Cancer Treatment Group Study.
|
Cancer Invest
|
2001
|
0.76
|
|
39
|
Trimodality therapy for superior sulcus non-small cell lung cancer: Southwest Oncology Group-Intergroup Trial S0220.
|
Ann Thorac Surg
|
2014
|
0.75
|
|
40
|
Randomized Clinical Trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB Non-Small Cell Lung Cancer (NSCLC): Report of Cancer and Leukemia Group B (CALGB) Protocol 9633.
|
J Clin Oncol
|
2004
|
0.75
|
|
41
|
North Central Cancer Treatment Group--achievements and perspectives.
|
Semin Oncol
|
2008
|
0.75
|